Beta Bionics wins FDA clearance for Mint pump
Beta Bionics said the FDA cleared its Mint pump, which does not require recharging and integrates with continuous glucose monitors. The company also lowered full-year 2026 sales guidance to $121 million-$126 million from $131 million-$136 million.